Sustained On- and Off-Treatment Disease Control in Patients With Moderate-to-Severe Atopic Dermatitis Following 12-Week, Open-Label, Once-Daily Abrocitinib 200 Mg: A Post Hoc Analysis of the Phase 3 JADE REGIMEN Study. J of Skin 2026, 10 (2), s732. https://doi.org/10.25251/v9pqj003.